Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Sexually Transmitted Diseases

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 92 articles:
HTML format



Single Articles


    August 2022
  1. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    


    June 2022
  2. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available


    May 2022
  3. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available


  4. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    


  5. BURMAN B, Drutman SB, Fury MG, Wong RJ, et al
    Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
    Oral Oncol. 2022;128:105806.
    PubMed     Abstract available


    April 2022
  6. SARODE SC, Sarode GS, Sengupta N
    Strengthening koilocyte as a biomarker of HPV infection: A need of the hour.
    Oral Oncol. 2022;129:105891.
    PubMed    


  7. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available


  8. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available


    March 2022
  9. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available


  10. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available


    February 2022
  11. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available


  12. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available


  13. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available


    January 2022
  14. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available


  15. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    


    December 2021
  16. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available


  17. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    


    November 2021
  18. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available


  19. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available


  20. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available


    October 2021
  21. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available


  22. SHISHODIA G, Toledo RRG, Rong X, Zimmerman E, et al
    4NQO enhances differential activation of DNA repair proteins in HPV positive and HPV negative HNSCC cells.
    Oral Oncol. 2021;122:105578.
    PubMed     Abstract available


  23. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available


  24. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    


    September 2021
  25. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available


    August 2021
  26. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available


  27. FIACCHINI G, Benettini G, Trico D, Torregrossa L, et al
    Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis.
    Oral Oncol. 2021;119:105252.
    PubMed     Abstract available


    July 2021
  28. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available


  29. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available


  30. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available


    June 2021
  31. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    PubMed     Abstract available


  32. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available


  33. BIDINOTTO AB, Kops NL, Bessel M, Maranhao AGK, et al
    Prevalence of oral HPV infection in unvaccinated young adults in Brazil.
    Oral Oncol. 2021;120:105396.
    PubMed     Abstract available


  34. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    PubMed     Abstract available


    May 2021
  35. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    


  36. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    


    April 2021
  37. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available


  38. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available


  39. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available


  40. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    


    March 2021
  41. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    PubMed     Abstract available


    February 2021
  42. FREIHAT O, Toth Z, Pinter T, Kedves A, et al
    Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC).
    Oral Oncol. 2021;116:105239.
    PubMed     Abstract available


  43. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    


  44. CHATFIELD-REED K, Roche VP, Pan Q
    cfDNA detection for HPV+ squamous cell carcinomas.
    Oral Oncol. 2021;115:104958.
    PubMed     Abstract available


  45. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    PubMed     Abstract available


    January 2021
  46. YILMAZ E, Ozbun MA, Gan GN
    Molecular and immune signature of HPV-positive oral cavity squamous cell carcinoma.
    Oral Oncol. 2021 Jan 25:105175. doi: 10.1016/j.oraloncology.2020.105175.
    PubMed    


  47. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available


  48. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    


    December 2020
  49. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available


    October 2020
  50. FLEMING CW, Ward MC, Woody NM, Joshi NP, et al
    Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Oral Oncol. 2020;112:105046.
    PubMed     Abstract available


  51. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2020;112:105041.
    PubMed     Abstract available


  52. CONTRERA KJ, Smile TD, Mahomva C, Wei W, et al
    Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
    Oral Oncol. 2020;111:105030.
    PubMed     Abstract available


    August 2020
  53. DICKSTEIN DR, Egerman MA, Bui AH, Doucette JT, et al
    A new face of the HPV epidemic: Oropharyngeal cancer in the elderly.
    Oral Oncol. 2020;109:104687.
    PubMed     Abstract available


  54. FAKHRY C, Fung N, Tewari SR, D'Souza G, et al
    Unique role of HPV16 in predicting oropharyngeal cancer risk more than other oncogenic oral HPV infections.
    Oral Oncol. 2020 Aug 29:104981. doi: 10.1016/j.oraloncology.2020.104981.
    PubMed    


    June 2020
  55. VIET CT, Dierks EJ, Cheng AC, Patel AA, et al
    Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival.
    Oral Oncol. 2020;109:104770.
    PubMed     Abstract available


  56. KREIMER AR, Chaturvedi AK, Alemany L, Anantharaman D, et al
    Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.
    Oral Oncol. 2020;108:104736.
    PubMed     Abstract available


  57. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    PubMed    


    May 2020
  58. JOO YH, Cho KJ, Kim GJ, Kim MS, et al
    Prognostic impact of resection margin involvement in surgically managed HPV-positive tonsil cancer.
    Oral Oncol. 2020;108:104806.
    PubMed     Abstract available


  59. KYLMA AK, Jouhi L, Mohamed H, Randen-Brady R, et al
    In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.
    Oral Oncol. 2020;107:104778.
    PubMed     Abstract available


    April 2020
  60. SCHROEDER L, Pring M, Ingarfield K, Pawlita M, et al
    HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer.
    Oral Oncol. 2020;107:104721.
    PubMed     Abstract available


  61. MOLONY P, Werner R, Martin C, Callanan D, et al
    The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104670.
    PubMed     Abstract available


  62. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    PubMed     Abstract available


  63. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    PubMed     Abstract available


    March 2020
  64. MAZUL AL, Colditz GA, Zevallos JP
    Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015.
    Oral Oncol. 2020;104:104609.
    PubMed     Abstract available


  65. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    PubMed    


    February 2020
  66. YIN X, Shan C, Wang J, Zhang H, et al
    Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;103:104590.
    PubMed     Abstract available


  67. FAKHRY C, Waterboer T, Westra WH, Rooper LM, et al
    Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.
    Oral Oncol. 2020;101:104522.
    PubMed     Abstract available


  68. CHARGI N, Bril SI, Swartz JE, Wegner I, et al
    Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104519.
    PubMed     Abstract available


    January 2020
  69. CHATFIELD-REED K, Gui S, O'Neill WQ, Teknos TN, et al
    HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.
    Oral Oncol. 2020;100:104488.
    PubMed     Abstract available


  70. CHEN C, Lohavanichbutr P, Zhang Y, Houck JR, et al
    Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples.
    Oral Oncol. 2020;100:104487.
    PubMed     Abstract available


    December 2019
  71. ESKANDER A, Husain ZA
    HPV testing: A quality metric.
    Oral Oncol. 2019 Dec 30:104549. doi: 10.1016/j.oraloncology.2019.104549.
    PubMed    


  72. BLACK M, Ghasemi F, Sun RX, Stecho W, et al
    Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
    Oral Oncol. 2019;101:104529.
    PubMed     Abstract available


  73. YOUNG RJ, Bressel M, Porceddu S, Cernelc J, et al
    Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2019;101:104516.
    PubMed     Abstract available


    November 2019
  74. STROBER W, Shishido S, Wood B, Lewis JS Jr, et al
    Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.
    Oral Oncol. 2019;100:104475.
    PubMed     Abstract available


  75. LU DJ, Luu M, Nguyen AT, Scher KS, et al
    Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.
    Oral Oncol. 2019;99:104472.
    PubMed     Abstract available


    October 2019
  76. MICCIO JA, Verma V, Kelly J, Kann BH, et al
    Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition.
    Oral Oncol. 2019;99:104447.
    PubMed     Abstract available


    September 2019
  77. VAN HARTEN AM, Poell JB, Buijze M, Brink A, et al
    Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    Oral Oncol. 2019;98:53-61.
    PubMed     Abstract available


    June 2019
  78. MCMULLEN CP, Garneau J, Weimar E, Ali S, et al
    Occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS with bilateral neck dissection.
    Oral Oncol. 2019;93:96-100.
    PubMed     Abstract available


    March 2019
  79. GHANIZADA M, Jakobsen KK, Gronhoj C, von Buchwald C, et al
    The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2019;90:67-73.
    PubMed     Abstract available


  80. FRIEDMAN J, Padget M, Lee J, Schlom J, et al
    Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
    Oral Oncol. 2019;90:38-44.
    PubMed     Abstract available


    February 2019
  81. ROSS RB, Juloori A, Varra V, Ward MC, et al
    Five-year outcomes of sparing level IB in node-positive, human papillomavirus-associated oropharyngeal carcinoma: A safety and efficacy analysis.
    Oral Oncol. 2019;89:66-71.
    PubMed     Abstract available


  82. MESHMAN J, Velez MA, Wang PC, Abemayor E, et al
    Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status.
    Oral Oncol. 2019;89:121-126.
    PubMed     Abstract available


    January 2019
  83. PAOLINI F, Bonomo C, Terrenato I, Pennetti A, et al
    Beta human papillomaviruses in middle ear squamous cell carcinoma.
    Oral Oncol. 2019 Jan 18. pii: S1368-8375(19)30004.
    PubMed    


    November 2018
  84. EVANS M, Beasley M
    Target delineation for postoperative treatment of head and neck cancer.
    Oral Oncol. 2018;86:288-295.
    PubMed     Abstract available


    October 2018
  85. AMBATIPUDI S, Langdon R, Richmond RC, Suderman M, et al
    DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
    Oral Oncol. 2018;85:87-94.
    PubMed     Abstract available


  86. LEE DJ, Eun YG, Rho YS, Kim EH, et al
    Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Oral Oncol. 2018;85:44-51.
    PubMed     Abstract available


    September 2018
  87. CHEN MM, Colevas AD, Megwalu U, Divi V, et al
    Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Oral Oncol. 2018;84:71-75.
    PubMed     Abstract available


    June 2018
  88. FERRIS RL, Blumenschein G Jr, Fayette J, Guigay J, et al
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol. 2018;81:45-51.
    PubMed     Abstract available


  89. OSAZUWA-PETERS N, Arnold LD, Loux TM, Varvares MA, et al
    Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis.
    Oral Oncol. 2018;81:29-34.
    PubMed     Abstract available


    May 2018
  90. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Abstract available


    February 2018
  91. PAI SI, Jack Lee J, Carey TE, Westra WH, et al
    HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Oral Oncol. 2018;77:92-97.
    PubMed     Abstract available


  92. VAN DEN BOVENKAMP K, Dorgelo B, Noordhuis MG, van der Laan BFAM, et al
    Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.
    Oral Oncol. 2018;77:131-136.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: